Home / Themes / MedTech Long '25: Mental Health
MedTech Long '25: Mental Health
Last updated
Theme thesis · 2/5 sections · Tickers 0 with notes · 7 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis basket is levered to RFK Jr.'s and Trump 2.0's mental health-first policy agenda, which favors non-pharma treatments, alternative therapies, and digital de
Thesis
This basket is levered to RFK Jr.'s and Trump 2.0's mental health-first policy agenda, which favors non-pharma treatments, alternative therapies, and digital delivery platforms. With federal support growing for psychedelic research, non-invasive interventions, and broader access via telehealth and primary care, these names benefit from structural reimbursement tailwinds, policy alignment, and the shift away from legacy psychiatric drugs.
Bull case
RFK is prioritizing mental health: HHS leadership has explicitly supported non-pharma approaches like TMS and wellness centers, with legislation expanding access and funding to non-traditional care models
Medicare Advantage tailwinds help platforms: CMS's MA rate hikes and integration of mental health into covered benefits favor TALK, STIM, and BWAY's telehealth and device-based solutions
Policy + tech unlock psychedelic infrastructure: MNMD and STIM stand to benefit from cultural and clinical momentum around psychedelic therapies and TMS as non-addictive alternatives to traditional psychiatric medications
Bear case
Cultural stigma or regulatory reversals stall momentum: Shifts in public sentiment or congressional resistance could delay broader adoption of alternative treatments like TMS or psychedelics.
Medicaid and CMS budget cuts reduce volume: Mental health reimbursements could come under pressure in budget-tightening cycles, particularly for out-of-network and non-core interventions.
Competition from generics and mainstream therapies: Cheap oral psychiatric drugs may regain favor among payers, limiting market share expansion for device-based or novel treatment providers.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Prescription volume trends for SSRIs vs. TMS/psychedelics | Monthly | Shows substitution away from pharma to alternative interventions like STIM, MNMD. | Google_Sheets |
| Medicare Advantage plan mental health coverage rates | Annual / Updates | Scope of reimbursement and access for telehealth and device therapies. | Google_Sheets |
| Mental health outpatient and telehealth utilization trends | Monthly / Quarterly | Measures demand and patient access for platforms like TALK, BWAY, and NPCE. | Google_Sheets |
Constituents
- ATAIT3· no notes yet
- AXSMT3· no notes yet
- CMPST3· no notes yet
- DFTXT3· no notes yet
- PCRXT3· no notes yet
- STIMT3· no notes yet
- TALKT3· no notes yet